 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | Niclonex (niclosamide suspension) / Imuneks
Journal: The Biosafety Evaluation for Crustaceans: A Novel Molluscicide PBQ Using against Oncomelania hupensis, the Intermediate Host of Schistosoma japonica. (Pubmed Central) - Oct 27, 2022
PBQ (20% SC), 26% metaldehyde, and niclosamide suspension concentrate [MNSC (26% SC)] were used both in ditch and field experiments for the molluscicidal efficacy comparison...Furthermore, it showed lower toxicity to the crustacean species, better solubility, no floating dust, and convenience for carriage. PBQ (20% SC) was suitable for controlling snails in the water network schistosomiasis-endemic areas.
- | Niclonex (niclosamide suspension) / Imuneks
Journal, HEOR: Effectiveness and cost analysis of two chemical molluscicides in hilly schistosomiasis-endemic regions (Pubmed Central) - Nov 21, 2021
PBQ (20% SC) was suitable for controlling snails in the water network schistosomiasis-endemic areas. 80% NESWP shows a high molluscicidal efficacy and low cost in hilly schistosomiasis-endemic regions.
- |||||||| Niclonex (niclosamide suspension) / Imuneks
New P3 trial: NICLONEX: A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19 (clinicaltrials.gov) - Sep 21, 2020
P3, N=200, Recruiting, Sponsor: Imuneks Farma ilac San. Tic. A.S.